☆ 4.6 Letter

Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)

Journal

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Volume 80, Issue 6, Pages 1780-1782

Publisher

MOSBY-ELSEVIER

DOI: 10.1016/j.jaad.2018.12.020

Keywords

-

Categories

Dermatology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors

Razvan Cristescu, Deepti Aurora-Garg, Andrew Albright, Lei Xu, Xiao Qiao Liu, Andrey Loboda, Lixin Lang, Fan Jin, Eric H. Rubin, Alexandra Snyder, Jared Lunceford

Summary: This study evaluated the relationship between tumor mutational burden (TMB) and the efficacy of immune checkpoint inhibitors. The results showed that high TMB is associated with improved efficacy of pembrolizumab monotherapy, regardless of tumor type, PD-L1 expression, or MSI status.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Medicine, General & Internal

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer

Ryon P. Graf, Virginia Fisher, Janick Weberpals, Ole Gjoerup, Marni B. Tierno, Richard S. P. Huang, Nicolas Sayegh, Douglas Lin, Kira Raskina, Alexa B. Schrock, Eric Severson, James F. Haberberger, Jeffrey S. Ross, James Creeden, Mia A. Levy, Brian M. Alexander, Geoffrey R. Oxnard, Neeraj Agarwal

Summary: This study compared the treatment outcomes of immune checkpoint inhibitors (ICI) and taxane chemotherapy in mCRPC patients based on tumor mutational burden (TMB). The results showed that ICI was more effective than taxanes in patients with high TMB, but not in those with low TMB.

JAMA NETWORK OPEN (2022)

Add to Collection

Article Oncology

Normalization of electroretinogram and symptom resolution of melanoma-associated retinopathy with negative autoantibodies after treatment with programmed death-1 (PD-1) inhibitors for metastatic melanoma

Karam Khaddour, Sangeeta Khanna, Michael Ansstas, Ishaan Jakhar, Sonika Dahiya, Laurin Council, George Ansstas

Summary: MAR is a paraneoplastic syndrome involving autoantibodies that can target retinal epitopes, historically treated with surgery or immunosuppressive medication. The use of glucocorticoids may reduce immunotherapy efficacy, while PD-1 inhibitors show potential in improving MAR by normalizing electroretinogram and reducing autoantibodies, emphasizing the importance of a multidisciplinary approach.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Add to Collection

Article Dermatology

Dermatological adverse events under programmed cell death-1 inhibitors as a prognostic marker in metastatic melanoma

Rony Shreberk-Hassidim, Lilach Aizenbud, Shalev Lussheimer, Elena Thomaidou, Tali Bdolah-Abram, Sharon Merims, Aron Popovtzer, Alex Maly, Michal Lotem, Abraham Zlotogorski

Summary: PD-1 inhibitors are commonly used in the treatment of melanoma, but they can lead to immune-related adverse events (cIRAE), including skin manifestations. This study found that cIRAE were common among melanoma patients treated with PD-1 inhibitors, and their occurrence may be associated with better treatment response and lower mortality rates.

DERMATOLOGIC THERAPY (2022)

Add to Collection

Article Oncology

Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors

Camila B. Xavier, Carlos Diego H. Lopes, Beatriz M. Awni, Eduardo F. Campos, Joao Pedro B. Alves, Anamaria A. Camargo, Gabriela D. A. Guardia, Pedro A. F. Galante, Denis L. Jardim

Summary: By analyzing the outcomes of patients with high TMB tumors treated with immune checkpoint inhibitors, this study found that combining the mutation profiles and TMB levels can better select patients for ICI treatment and predict their overall survival.

CANCERS (2022)

Add to Collection

Article Oncology

Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma

Robert Haddad, Tanguy Y. Seiwert, Laura Q. M. Chow, Shilpa Gupta, Jared Weiss, Iris Gluck, Joseph P. Eder, Barbara Burtness, Makoto Tahara, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Andrew Albright, Robin Mogg, Mark Ayers, Lingkang Huang, Jared Lunceford, Razvan Cristescu, Jonathan Cheng, Ranee Mehra

Summary: This study found that tumor mutational burden (TMB), neoantigen load (NL), and T-cell-inflamed gene expression profile (Tcell(inf)GEP) were associated with response, and inflammatory biomarkers (Tcell(inf)GEP and PD-L1) showed a trend towards clinical response. The study also found concordance between HPV status detected by whole exome sequencing (WES) and p16 immunohistochemistry. These findings contribute to predicting response to anti-PD-1 therapy.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Review Oncology

Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities

Romualdo Barroso-Sousa, Jana Priscila Pacifico, Sarah Sammons, Sara M. Tolaney

Summary: Tumor mutational burden (TMB) correlates with tumor neoantigen burden, T cell infiltration, and response to immune checkpoint inhibitors in many solid tumor types. However, limited data exist regarding the true role of TMB as a predictive biomarker of benefit to immunotherapy in breast cancer. This review discusses the challenges and opportunities in establishing TMB as a predictive biomarker of benefit to immunotherapy in metastatic breast cancer.

CANCERS (2023)

Add to Collection

Article Oncology

PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations

Tiantian Ma, Jin Jiao, Ran Huo, Xiaofang Li, Guotao Fang, Qi Zhao, Weiwei Liu, Xiao Han, Chenglin Xi, Yanan Wang, Yanhong Shang

Summary: PD-1/PD-L1 inhibitors appear to be less effective in NSCLC patients with EGFR mutations. However, some rare EGFR mutation subtypes may benefit from this therapy. PD-L1 expression, TMB, and immune cell infiltration are biomarkers for predicting the efficacy of PD-1/PD-L1 inhibitors in NSCLC patients.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Tumor Mutational Burden for Predicting Prognosis and Therapy Outcome of Hepatocellular Carcinoma

Daniela Gabbia, Sara De Martin

Summary: Hepatocellular carcinoma (HCC) is the second-leading cause of cancer-related death globally, and efforts have been made to find novel biomarkers for predicting patients' survival and treatment outcomes, especially in immunotherapy. The role of tumor mutational burden (TMB), the total number of mutations per coding area of a tumor genome, has been studied to determine whether it could be a reliable biomarker for stratifying HCC patients into subgroups with different responsiveness to immunotherapy or predicting disease progression, particularly in relation to different HCC etiologies. This review summarizes the recent advances in studying TMB and TMB-related biomarkers in HCC, focusing on their feasibility as guides for therapy decisions and predictors of clinical outcomes.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Oncology

Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study

Irene M. Shui, Xiao Qiao Liu, Qing Zhao, Seung Tae Kim, Yuan Sun, Jennifer H. Yearley, Tasmiah Choudhury, Andrea L. Webber, Clemens Krepler, Razvan Cristescu, Jeeyun Lee

Summary: This study suggests that Tcell(inf)GEP and PD-L1 expression, TMB, immune cell infiltration, and RAS and WNT signaling may be potential mechanisms and/or biomarkers of anti-PD-1 therapy resistance in acral and mucosal melanomas. Confirmation of these findings in larger populations is needed.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Oncology

Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade

Giovanni Randon, Yu Aoki, Romain Cohen, Leonardo Provenzano, Vincenzo Nasca, Samuel J. Klempner, Steven B. Maron, Riccardo Cerantola, Joseph Chao, Lorenzo Fornaro, Walter Ferrari Bravo, Filippo Ghelardi, Margherita Ambrosini, Paolo Manca, Massimiliano Salati, Akihito Kawazoe, Valerie Zhu, Darren Cowzer, Virginia Genovesi, Sara Lonardi, Kohei Shitara, Thierry Andre, Filippo Pietrantonio

Summary: This study found that immune checkpoint inhibitor-based therapy is superior to chemotherapy in patients with dMMR and/or MSI-high advanced gastric or gastroesophageal junction adenocarcinoma. However, more studies are needed to examine prognostic features within this patient population.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Add to Collection

Article Oncology

PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma

Geoffrey T. Gibney, Jacob Zaemes, Shelly Shand, Neil J. Shah, David Swoboda, Kellie Gardner, Arash Radfar, Vesna Petronic-Rosic, Michael J. Reilly, Waddah B. Al-Refaie, Suthee Rapisuwon, Michael B. Atkins

Summary: A retrospective study of 122 patients with advanced melanoma treated with anti PD-1 therapy found that discontinuation of treatment after 12 months when no active disease is observed on imaging or biopsy may have low rates of disease relapse. Biopsy of residual disease may frequently lead to a change in management.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Oncology

SETD2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy

Xiaobin Zheng, Jing Lin, Jiani Xiong, Yanfang Guan, Bin Lan, Yi Li, Xuan Gao, Zhaodong Fei, Lisha Chen, Lizhu Chen, Ling Chen, Gang Chen, Zengqing Guo, Xin Yi, Weiguo Cao, Xinghao Ai, Chengzhi Zhou, Xiaofeng Li, Jun Zhao, Xiangtao Yan, Qitao Yu, Lu Si, Yu Chen, Chuanben Chen

Summary: This study found that SETD2 dysfunction affects the prognosis of immunotherapy independently of TMB-H and has a lower death hazard than TMB-H in pancancer patients. Therefore, SETD2 has the potential to serve as a candidate biomarker for immunotherapy, and should be considered when dMMR is detected by immunohistochemistry.

BMC CANCER (2023)

Add to Collection

Article Oncology

Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer

Yunfei Shi, Youming Lei, Li Liu, Shiyue Zhang, Wenjing Wang, Juan Zhao, Songhui Zhao, Xiaowei Dong, Ming Yao, Kai Wang, Qing Zhou

Summary: This study aimed to explore novel biomarkers for immune checkpoint inhibitor responses in non-small cell lung cancer (NSCLC) by integrating genomic profiling, tumor mutational burden (TMB), and PD-L1 expression. The study identified that tumors with different alterations in actionable target genes had variable expression of PD-L1 and TMB in NSCLC, and suggested that TP53/KMT2C co-mutation might serve as a predictive biomarker for ICI responses in NSCLC.

CANCER MEDICINE (2021)

Add to Collection

Article Oncology

Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden

Vaia Florou, Charalampos S. Floudas, Asaf Maoz, Abdul Rafeh Naqash, Carter Norton, Aik Choon Tan, Ethan S. Sokol, Garrett Frampton, Heloisa P. Soares, Sonam Puri, Umang Swami, Breelyn Wilky, Peter Hosein, Jonathan Trent, Gilberto de Lima Lopes, Wungki Park, Ignacio Garrido-Laguna

Summary: This study found that frameshift mutations (FSs) can serve as a predictive biomarker for immunotherapy response in solid tumors with microsatellite stability and low tumor mutational burden (TMB).

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Add to Collection

Article Oncology

Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions

Zachary R. Chalmers, Michael C. Burns, Ericka M. Ebot, Garrett M. Frampton, Jeffrey S. Ross, Maha H. A. Hussain, Sarki A. Abdulkadir

Summary: In summary, early-onset prostate cancer patients with clinically advanced and metastatic disease display distinct molecular alterations compared to older patients, with increased frequency of TMPRSS2-ERG fusions and fewer AR, SPOP, and ASXL1 alterations.

PROSTATE CANCER AND PROSTATIC DISEASES (2021)

Add to Collection

Article Oncology

Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression

Richard S. P. Huang, Karthikeyan Murugesan, Meagan Montesion, Dean C. Pavlick, Douglas A. Mata, Matthew C. Hiemenz, Brennan Decker, Garrett Frampton, Lee A. Albacker, Jeffrey S. Ross

Summary: The study analyzed a large cohort of solid tumor cases to investigate CD274 copy-number changes and their correlation with PD-L1 protein expression. The prevalence of CD274 copy-number changes varied across different tumor types and was found to be significantly associated with PD-L1 positivity in certain tumor types, indicating its potential as a biomarker for immune checkpoint inhibitor therapy.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Oncology

Prediction and characterization of diffuse large B-cell lymphoma cell-of-origin subtypes using targeted sequencing

Sally E. Trabucco, Ethan S. Sokol, Sophia L. Maund, Jay A. Moore, Garrett M. Frampton, Lee A. Albacker, Mikkel Z. Oestergaard, Jeffrey Venstrom, Laurie H. Sehn, Christopher R. Bolen

Summary: This study successfully identified the subtypes of diffuse large B-cell lymphoma (DLBCL) using DNA mutation-based tools, determined associated features, and confirmed the origins of GCB and ABC subtypes.

FUTURE ONCOLOGY (2021)

Add to Collection

Article Oncology

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

Marcelo Negrao, Ferdinandos Skoulidis, Meagan Montesion, Katja Schulze, Ilze Bara, Vincent Shen, Hao Xu, Sylvia Hu, Dawen Sui, Yasir Y. Elamin, Xiuning Le, Michael E. Goldberg, Karthikeyan Murugesan, Chang-Jiun Wu, Jianhua Zhang, David S. Barreto, Jacqulyne P. Robichaux, Alexandre Reuben, Tina Cascone, Carl M. Gay, Kyle G. Mitchell, Lingzhi Hong, Waree Rinsurongkawong, Jack A. Roth, Stephen G. Swisher, Jack Lee, Anne Tsao, Vassiliki Papadimitrakopoulou, Don L. Gibbons, Bonnie S. Glisson, Gaurav Singal, Vincent A. Miller, Brian Alexander, Garrett Frampton, Lee A. Albacker, David Shames, Jianjun Zhang, John Heymach

Summary: High TMB and PD-L1 expression are predictive for benefit from ICB treatment in oncogene-driven NSCLCs. NSCLC harboring BRAF mutations demonstrated superior benefit from ICB that may be attributed to higher TMB and higher PD-L1 expression in these tumors.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Oncology

Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors

Jonathan W. Riess, Shaila Rahman, Waleed Kian, Claire Edgerly, Andreas M. Heilmann, Russell Madison, Shakti H. Ramkissoon, Shai Shlomi Klaitman, Jon H. Chung, Sally E. Trabucco, Dexter X. Jin, Brian M. Alexander, Samuel J. Klempner, Lee A. Albacker, Garrett M. Frampton, Laila C. Roisman, Vincent A. Miller, Jeffrey S. Ross, Alexa B. Schrock, Jeffrey P. Gregg, Nir Peled, Ethan S. Sokol, Siraj M. Ali

Summary: This study investigated the relationship between the BRD4-NUT translocation and solid tumors, explored the therapeutic effects of immune checkpoint inhibitors on these tumors, and proposed that high binding affinity may be the underlying mechanism of treatment response.

TRANSLATIONAL ONCOLOGY (2021)

Add to Collection

Article Genetics & Heredity

Intra-patient stability of tumor mutational burden from tissue biopsies at different time points in advanced cancers

Timothy V. Pham, Aaron M. Goodman, Smruthy Sivakumar, Garrett Frampton, Razelle Kurzrock

Summary: The study found that there was no significant difference in TMB between different tumor biopsies from the same patient, but TMB may increase in patients receiving ICI treatment. In general, tissue TMB remains stable over time, with specific therapies such as immunotherapy potentially leading to an increase in TMB.

GENOME MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors

Coren A. Milbury, James Creeden, Wai-Ki Yip, David L. Smith, Varun Pattani, Kristi Maxwell, Bethany Sawchyn, Ole Gjoerup, Wei Meng, Joel Skoletsky, Alvin D. Concepcion, Yanhua Tang, Xiaobo Bai, Ninad Dewal, Pei Ma, Shannon T. Bailey, James Thornton, Dean C. Pavlick, Garrett M. Frampton, Daniel Lieber, Jared White, Christine Burns, Christine Vietz

Summary: FoundationOne (R) CDx is an FDA-approved companion diagnostic test that utilizes comprehensive genomic profiling technology to analyze 324 cancer genes in solid tumors. It accurately identifies patients who may benefit from specific drug therapies and helps improve treatment outcomes for cancer patients.

PLOS ONE (2022)

Add to Collection

Article Multidisciplinary Sciences

Comprehensive characterization of PTEN mutational profile in a series of 34,129 colorectal cancers

Ilya G. Serebriiskii, Valery Pavlov, Rossella Tricarico, Grigorii Andrianov, Emmanuelle Nicolas, Mitchell Parker, Justin Newberg, Garrett Frampton, Joshua E. Meyer, Erica A. Golemis

Summary: Loss or dysfunction of the PTEN tumor suppressor gene can activate pro-tumorigenic signaling pathways. In this study, the authors analyze sequencing data from a large cohort of colorectal cancer patients with PTEN mutations and identify distinct patterns of associations with genomic and clinical features.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Genetics & Heredity

A pan-cancer landscape of telomeric content shows that RAD21 and HGF alterations are associated with longer telomeres

Radwa Sharaf, Meagan Montesion, Julia F. Hopkins, Jiarong Song, Garrett M. Frampton, Lee A. Albacker

Summary: This study highlights the importance of RAD21 and HGF in telomere lengthening, supporting unlimited replication in tumors. These findings open avenues for work aimed at targeting this crucial pathway in tumorigenesis.

GENOME MEDICINE (2022)

Add to Collection

Article Oncology

ERBB2 Copy Number as a Quantitative Biomarker for Real-World Outcomes to Anti-Human Epidermal Growth Factor Receptor 2 Therapy in Advanced Gastroesophageal Adenocarcinoma

Liangliang Zhang, Omar Hamdani, Ole Gjoerup, Cheryl Cho-Phan, Jeremy Snider, Emily Castellanos, Halla Nimeiri, Garrett Frampton, Jeffrey M. Venstrom, Geoffrey Oxnard, Samuel J. Klempner, Alexa B. Schrock

Summary: This study aimed to explore the characteristics of HER2 amplification in gastroesophageal adenocarcinoma (GEA) patients and investigate its association with the efficacy of trastuzumab. The results showed that the copy number of ERBB2 in HER2-amplified patients could predict progression-free survival in trastuzumab-treated patients. This study contributes to a better understanding of the importance of HER2 amplification in the treatment of GEA.

JCO PRECISION ONCOLOGY (2022)

Add to Collection

Article Biochemical Research Methods

Analytical protocol to identify local ancestry-associated molecular features in cancer

Jian Carrot-Zhang, Seunghun Han, Wanding Zhou, Jeffrey S. Damrauer, Anab Kemal, Rameen Canc Genome Atlas Anal Network, Andrew D. Cherniack, Rameen Beroukhim

Summary: This protocol presents a method to identify local ancestry and detect associated molecular changes in admixed populations, utilizing data from the Cancer Genome Atlas. It can be applied to examine germline contributions to cancer in patients with mixed ancestries. For more detailed information, refer to Carrot-Zhang et al. (2020).

STAR PROTOCOLS (2021)

Add to Collection

Article Oncology

Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns

Jessica K. Lee, Russell Madison, Anthony Classon, Ole Gjoerup, Mark Rosenzweig, Garrett M. Frampton, Brian M. Alexander, Geoffrey R. Oxnard, Jeffrey M. Venstrom, Mark M. Awad, Alexa B. Schrock

Summary: METex14 skipping alterations are oncogenic drivers in a subset of NSCLC patients, comprising 2%-3% of cases. Tissue and liquid samples show high concordance in mutation profiles, indicating potential for predicting responses to MET inhibitors and combination strategies.

JCO PRECISION ONCOLOGY (2021)

Add to Collection

Article Oncology

Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry

Richard S. P. Huang, Eric Severson, James Haberberger, Daniel L. Duncan, Amanda Hemmerich, Claire Edgerly, N. Lynn Ferguson, Garrett Frampton, Clarence Owens, Erik Williams, Julia Elvin, Jo-Anne Vergilio, Jonathan Keith Killian, Douglas Lin, Samantha Morley, Deborah McEwan, Oliver Holmes, Natalie Danziger, Michael B. Cohen, Pratheesh Sathyan, Kimberly McGregor, Prasanth Reddy, Jeffrey Venstrom, Rachel Anhorn, Brian Alexander, Charlotte Brown, Jeffrey S. Ross, Shakti H. Ramkissoon

Summary: By combining CGP with PD-L1 IHC, actionable results were obtained for 70.5% of NSCLC patients, with an additional 86.7% potentially eligible for other biomarker-associated therapies or clinical trials. This highlights the improved clinical utility of using both CGP and IHC for expanding biomarker-guided therapeutic options in NSCLC patients.

PATHOLOGY & ONCOLOGY RESEARCH (2021)

Add to Collection

Article Medicine, General & Internal

Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors

Changxia Shao, Gerald Li, Lingkang Huang, Scott Pruitt, Emily Castellanos, Garrett Frampton, Kenneth R. Carson, Tamara Snow, Gaurav Singal, David Fabrizio, Brian M. Alexander, Fan Jin, Wei Zhou

JAMA NETWORK OPEN (2020)

Add to Collection

Article Oncology

Tumor mutational burden is not predictive of cytotoxic chemotherapy response

Mina Nikanjam, Paul Riviere, Aaron Goodman, Donald A. Barkauskas, Garrett Frampton, Razelle Kurzrock

ONCOIMMUNOLOGY (2020)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.